MA53382B1 - Composés co-agonistes de gip/glp1 - Google Patents

Composés co-agonistes de gip/glp1

Info

Publication number
MA53382B1
MA53382B1 MA53382A MA53382A MA53382B1 MA 53382 B1 MA53382 B1 MA 53382B1 MA 53382 A MA53382 A MA 53382A MA 53382 A MA53382 A MA 53382A MA 53382 B1 MA53382 B1 MA 53382B1
Authority
MA
Morocco
Prior art keywords
compounds
relates
present
glp1
gip
Prior art date
Application number
MA53382A
Other languages
English (en)
Other versions
MA53382A (fr
Inventor
Jorge Alsina-Fernandez
Robert Chadwick Cummins
Tamer Coskun
Hongchang Qu
Over Cabrera
Milata Mary Abraham
Aktham Aburub
Robert Andrew Brown
Amita DATTA-MANNAN
Mohamed Elsayed Hamed Elsayed
Xianyin Lai
Phenil Jayantilal Patel
Kyle Wynn Sloop
Thi Thanh Huyen TRAN
James Lincoln Wallis
Francis Stafford Willard
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA53382A publication Critical patent/MA53382A/fr
Publication of MA53382B1 publication Critical patent/MA53382B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des composés ayant une activité au niveau du polypeptide insulinotrope dépendant du glucose humain (GIF) et de récepteurs de peptide-1 de type glucagon (GLP-1). La présente invention concerne également des composés ayant une durée d'action prolongée au niveau de chacun de ces récepteurs. En outre, la présente invention concerne des composés qui peuvent être administrés par voie orale. Les composés peuvent être utiles dans le traitement du diabète sucré de type 2 ("T2DM"). De plus, les composés peuvent être utilisés dans le traitement de l'obésité.
MA53382A 2018-07-23 2019-07-22 Composés co-agonistes de gip/glp1 MA53382B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862702072P 2018-07-23 2018-07-23
US201862730563P 2018-09-13 2018-09-13
US201862740596P 2018-10-03 2018-10-03
EP19753218.7A EP3827015B1 (fr) 2018-07-23 2019-07-22 Composés co-agonistes de gip/glp1
PCT/US2019/042822 WO2020023386A1 (fr) 2018-07-23 2019-07-22 Composés co-agonistes de gip/glp1

Publications (2)

Publication Number Publication Date
MA53382A MA53382A (fr) 2021-06-02
MA53382B1 true MA53382B1 (fr) 2026-04-30

Family

ID=67620523

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53382A MA53382B1 (fr) 2018-07-23 2019-07-22 Composés co-agonistes de gip/glp1

Country Status (36)

Country Link
US (3) US11084861B2 (fr)
EP (2) EP3827015B1 (fr)
JP (3) JP6920559B2 (fr)
KR (3) KR102351313B1 (fr)
CN (2) CN119504975A (fr)
AU (2) AU2019311000B2 (fr)
BR (1) BR112020026671A2 (fr)
CA (3) CA3107345C (fr)
CL (1) CL2021000158A1 (fr)
CO (1) CO2021000453A2 (fr)
CR (1) CR20210040A (fr)
DK (1) DK3827015T3 (fr)
DO (1) DOP2021000016A (fr)
EC (1) ECSP21004913A (fr)
ES (1) ES3068975T3 (fr)
FI (1) FI3827015T3 (fr)
HR (1) HRP20260584T1 (fr)
IL (1) IL279827A (fr)
JO (2) JOP20210016A1 (fr)
LT (1) LT3827015T (fr)
MA (1) MA53382B1 (fr)
MX (1) MX2021000793A (fr)
MY (1) MY197569A (fr)
PE (2) PE20211637A1 (fr)
PH (1) PH12021550154A1 (fr)
PL (1) PL3827015T3 (fr)
PT (1) PT3827015T (fr)
RS (1) RS68018B1 (fr)
SA (1) SA521421080B1 (fr)
SG (1) SG11202100128UA (fr)
SI (1) SI3827015T1 (fr)
SM (1) SMT202600231T1 (fr)
TW (5) TWI863239B (fr)
UA (1) UA129537C2 (fr)
WO (1) WO2020023386A1 (fr)
ZA (3) ZA202100235B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
ES3068975T3 (en) * 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
AU2019309798A1 (en) 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
WO2021034815A1 (fr) 2019-08-19 2021-02-25 Eli Lilly And Company Procédés de fabrication d'analogues d'incrétine
EP4069726A4 (fr) 2019-12-04 2024-03-20 The Scripps Research Institute Agonistes du récepteur glp2 et méthodes d'utilisation
CA3165430A1 (fr) * 2020-01-23 2021-07-29 Jorge Alsina-Fernandez Composes co-agonistes de gip/glp1
WO2021175974A1 (fr) 2020-03-06 2021-09-10 Sanofi Peptides servant d'agonistes sélectifs du récepteur gip
EP4171662A1 (fr) 2020-03-31 2023-05-03 Antaros Medical AB Agonistes sélectifs du récepteur de gip comprenant une fraction chélatante à des fins d'imagerie et de thérapie
CN118754965A (zh) 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
JP2023534130A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
JP7738659B2 (ja) * 2020-12-22 2025-09-12 イーライ リリー アンド カンパニー 治療用ペプチド製剤
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3208873A1 (fr) 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Procedes therapeutiques agonistes doubles gip/glp1
TW202423476A (zh) * 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
US12215133B2 (en) 2021-03-25 2025-02-04 Brightgene Bio-Medical Technology Co., Ltd. GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
CA3213261A1 (fr) * 2021-03-25 2022-09-29 Jiandong Yuan Agoniste du recepteur double gip et glp-1, composition pharmaceutique et utilisation
AU2022269659B2 (en) * 2021-05-07 2025-04-10 Eli Lilly And Company Erodible tablet
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN117866050A (zh) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 多肽的制备及其应用
WO2022253202A1 (fr) * 2021-06-01 2022-12-08 南京知和医药科技有限公司 Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN115594752A (zh) * 2021-07-07 2023-01-13 成都奥达生物科技有限公司（Cn） 一种长效双激动剂化合物
WO2023031455A1 (fr) 2021-09-06 2023-03-09 Sanofi Sa Nouveaux peptides utilisés en tant qu'agonistes puissants et sélectifs du récepteur de gip
CA3231953A1 (fr) 2021-09-15 2023-03-23 Brian Lian Compositions et methodes de traitement de troubles metaboliques et hepatiques
KR20240099485A (ko) * 2021-11-19 2024-06-28 메드샤인 디스커버리 아이엔씨. 스테이플화 펩타이드 및 이의 용도
KR20240118786A (ko) * 2021-12-01 2024-08-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
JP7886963B2 (ja) * 2022-04-07 2026-07-08 広東衆生睿創生物科技有限公司 糖尿病、肥満症およびその関連疾患を治療および／または予防するための医薬品の調製における、ポリペプチドの医薬的使用
WO2024010379A1 (fr) * 2022-07-05 2024-01-11 주식회사 지투지바이오 Formulation de microsphères à libération prolongée comprenant du sémaglutide ou son sel pharmaceutiquement acceptable et procédé de préparation associé
CN117402219B (zh) * 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
JP2025523981A (ja) * 2022-07-20 2025-07-25 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための医薬製剤及び方法
KR20250057847A (ko) 2022-08-29 2025-04-29 일라이 릴리 앤드 캄파니 경구 전달용 조성물
CN119894921A (zh) * 2022-09-15 2025-04-25 伊莱利利公司 Gip和glp-1双重激动剂化合物
EP4622998A2 (fr) * 2022-11-21 2025-10-01 Eli Lilly and Company Procédé de préparation d'un double agoniste gip/glp1
AU2024215381A1 (en) 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024165571A2 (fr) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
EP4724472A2 (fr) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Nouveaux agonistes du récepteur double glp-1/gip et glp-1/gcg
EP4741420A1 (fr) * 2023-06-30 2026-05-13 Huonslab Co., Ltd. Composition pharmaceutique pour prévenir ou traiter l'obésité comprenant un analogue de glp en tant que principe actif
CN122094977A (zh) * 2023-10-26 2026-05-26 齐鲁制药有限公司 具有多重激动活性的多肽及其应用
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
TWI926512B (zh) 2023-11-30 2026-05-21 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
CN117624333A (zh) * 2023-12-05 2024-03-01 江苏师范大学 一类GLP-1受体、glucagon受体和GIP受体三激动多肽化合物及其应用
WO2025125576A2 (fr) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (fr) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibiteurs d expression et/ou de fonction
CN122555713A (zh) * 2023-12-29 2026-08-11 杭州中美华东制药有限公司 Glp-1/gip双激动剂的固相合成方法
AU2025205709A1 (en) * 2024-01-05 2026-06-18 Indiana University Research And Technology Corporation Gip/glp-1 co-agonists and their associated prodrugs
WO2025149039A1 (fr) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 Composition pharmaceutique d'agoniste double de glp-1/gip à action prolongée
CN122535418A (zh) * 2024-01-12 2026-08-07 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的鼻腔递送药物组合物
WO2025161155A1 (fr) * 2024-02-04 2025-08-07 内蒙古博睿精创科技有限公司 Composé polypeptidique glp-1 à action prolongée, composition et utilisation associées
WO2025196502A1 (fr) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Inhibiteurs de choline kinase utilisés en tant que traitement thérapeutique contre l'obésité
TW202620038A (zh) * 2024-06-21 2026-05-16 美商紐羅克里生物科學有限公司 經化學修飾之肽及其用途
WO2025264809A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
WO2025264785A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
US20260158159A1 (en) * 2024-07-24 2026-06-11 Eli Lilly And Company Fc-ACYLATED POLYPEPTIDE CONJUGATES
WO2026060110A1 (fr) * 2024-09-12 2026-03-19 Protagonist Therapeutics, Inc. Composés agonistes doubles et triples pour l'obésité et le diabète de type 2
WO2026076425A1 (fr) 2024-10-04 2026-04-09 Biodrive, Inc. Plate-forme de bioadministration orale
KR102991397B1 (ko) 2024-11-29 2026-07-21 노보 노르디스크 에이/에스 Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도
GB202418179D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods
GB202418172D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790262B2 (en) * 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CA2872314C (fr) * 2012-05-03 2021-08-31 Zealand Pharma A/S Composes agonistes doubles du gip-glp-1 et methodes
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
CA2929459C (fr) * 2013-11-06 2022-05-03 Zealand Pharma A/S Composes agonistes doubles de gip et glp-1 et procedes associes
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
AR103242A1 (es) * 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016198604A1 (fr) * 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp-1/glucagon
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US10221965B2 (en) * 2015-12-22 2019-03-05 Engineered Controls International, Llc Noise reducing filler valve
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
ES3068975T3 (en) * 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds

Also Published As

Publication number Publication date
RS68018B1 (sr) 2026-05-29
JP2023171775A (ja) 2023-12-05
SG11202100128UA (en) 2021-02-25
SI3827015T1 (sl) 2026-06-30
TWI810606B (zh) 2023-08-01
TWI735917B (zh) 2021-08-11
SA521421080B1 (ar) 2024-11-04
ECSP21004913A (es) 2021-02-26
MY197569A (en) 2023-06-25
BR112020026671A2 (pt) 2021-04-06
SMT202600231T1 (it) 2026-07-16
AU2019311000A1 (en) 2021-02-25
TW202019952A (zh) 2020-06-01
CO2021000453A2 (es) 2021-01-29
DK3827015T3 (da) 2026-05-04
AU2023202709A1 (en) 2023-05-18
UA129537C2 (uk) 2025-05-28
FI3827015T3 (fi) 2026-04-30
DOP2021000016A (es) 2021-03-15
US20250122259A9 (en) 2025-04-17
CN112469731A (zh) 2021-03-09
WO2020023386A1 (fr) 2020-01-30
EP4549454A2 (fr) 2025-05-07
MX2021000793A (es) 2021-04-12
JP7626530B2 (ja) 2025-02-07
US11084861B2 (en) 2021-08-10
PE20260005A1 (es) 2026-01-06
US20200024322A1 (en) 2020-01-23
CA3178366A1 (fr) 2020-01-30
JP6920559B2 (ja) 2021-08-18
CR20210040A (es) 2021-02-12
JP2021508731A (ja) 2021-03-11
KR20210031533A (ko) 2021-03-19
ZA202105821B (en) 2025-07-30
PT3827015T (pt) 2026-04-24
EP3827015A1 (fr) 2021-06-02
MA53382A (fr) 2021-06-02
JOP20250198A1 (ar) 2025-08-03
TWI863239B (zh) 2024-11-21
KR20210016632A (ko) 2021-02-16
EP3827015B1 (fr) 2026-02-18
JOP20210016A1 (ar) 2021-01-21
EP4549454A3 (fr) 2025-07-09
AU2019311000B2 (en) 2023-02-02
HRP20260584T1 (hr) 2026-06-05
IL279827A (en) 2021-03-01
CN119504975A (zh) 2025-02-25
CA3107345C (fr) 2025-07-08
PE20211637A1 (es) 2021-08-24
KR20240051304A (ko) 2024-04-19
PH12021550154A1 (en) 2021-09-13
CL2021000158A1 (es) 2021-07-30
ES3068975T3 (en) 2026-06-03
TWI917014B (zh) 2026-03-01
CA3178366C (fr) 2026-02-24
CA3294907A1 (en) 2026-03-02
PL3827015T3 (pl) 2026-06-15
JP2021183614A (ja) 2021-12-02
CA3107345A1 (fr) 2020-01-30
ZA202106369B (en) 2025-01-29
KR102351313B1 (ko) 2022-01-17
ZA202100235B (en) 2025-03-26
TW202140527A (zh) 2021-11-01
TW202332688A (zh) 2023-08-16
US20220048967A1 (en) 2022-02-17
TW202523681A (zh) 2025-06-16
LT3827015T (lt) 2026-05-11
US20250051415A1 (en) 2025-02-13
TW202620037A (zh) 2026-05-16
US12252524B2 (en) 2025-03-18
CN112469731B (zh) 2024-11-29

Similar Documents

Publication Publication Date Title
ZA202106369B (en) Gip/glp1 co-agonist compounds
MX2026002524A (es) Compuestos agonistas de gipr
AR121093A1 (es) Compuestos coagonistas de gip / glp1
Martin et al. Incretin‐based therapies–review of the physiology, pharmacology and emerging clinical experience
Kim et al. The role of incretins in glucose homeostasis and diabetes treatment
Tella et al. DPP-4 inhibitors: focus on safety
MA41315A (fr) Composés co-agonistes de gip et de glp-1
PE20221518A1 (es) Analogos de incretina y sus usos
CN111278853A (zh) 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
JP2019510739A5 (fr)
EA201370099A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
JOP20200265A1 (ar) متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 (glp-1) واستخداماتها
JP2016522241A5 (fr)
McMahon A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction.
MX2026000195A (es) Triagonista de los receptores glp-1, gip y gcg y su uso
EA202192296A1 (ru) Терапевтическое применение дулаглутида
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
BRPI0506694A (pt) análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
TH2101000319A (th) สารประกอบอะโกนิสท์ร่วม gip/glp1
TH2201000489A (th) สารประกอบ gipr-อะโกนิสท์
EA202190830A1 (ru) Терапевтическое применение тройного агониста рецепторов глюкагона/glp-1/gip или его конъюгата против заболевания печени
TH2101006227A (th) ดูลากลูไทด์สำหรับการผลิตเภสัชภัณฑ์สำหรับผู้ป่วยที่มีเบาหวานชนิดที่ 2
MA52226B1 (fr) Nouveaux analogues de glp-1
Bailey Incretin-based therapies
Oskola et al. Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4